Safety Pharmacological studies of Kalyanaka ghrita

Diddi Sneha Latha (1) , Arulmozhi S (2)
(1) Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune – 411038, Maharashtra, India, India ,
(2) Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune – 411038, Maharashtra, India, India

Abstract

Safety pharmacology is a study of unfavorable, pharmacodynamic effects of a drug on physiological functions with therapeutic range by using International Conference on Harmonization (ICH) S7A guidelines. The cardiovascular, central nervous, and respiratory systems are most affected by pharmacological side effects, resulting withdrawal of multiple medications from the market. Kalyanaka ghrita (KG) is an Ayurvedic formulation with ghee as a major basic component, though a promising candidate in treatment of AD, KG has not been documented for its safety profile, which prompted the study. In this study we evaluated safety pharmacology of KG oral (4, 2, 1g/kg), and nasal (100, 50, 25 µl/rat), in Wistar rats for 28 days subjected to CNS, CVS and the respiratory safety profile was evaluated on day 0, 14 and 28. At the end of the study the nasal turbinate was evaluated histopathologically. In the present study KG did not cause any significant change in CNS profile. However KG treatment had increased the grooming and rearing behaviors, which were not significant compared to vehicle control and did not cause change in CVS and respiratory profile upon treatment with KG for 28 days. The epithelium of nasal turbinate of animals was found intact after 28 days of nasal administration. After sustained dosing, the KG oral and intranasal treated groups showed no harmful events, which illustrates the CNS, CVS and respiratory safety profile of Kalyanaka ghrita.

Full text article

Generated from XML file

References

Amen, E. M., Becker, E.-M., Truebel, H. 2011. Analysis of V/Q-matching—a safety “biomarker” in pulmonary drug development? Biomarkers, 16(sup1):5–10.

Baird, S. J. S., Catalano, P. J., Ryan, L. M., Evans, J. S. 1997. Evaluation of Effect Profiles: Functional Observational Battery Outcomes. Toxicological Sciences, 40(1):37–51.

Bargeton, D., Barres, G. 1969. Time characteristics and frequency response of body plethysmograph. In Body Plethysmography, 4:2–23. Karger Publishers.

Bass, A. S., Vargas, H. M., Kinter, L. B. 2004. Introduction to Nonclinical Safety Pharmacology and the Safety Pharmacology Society. Journal of Pharmacological and Toxicological Methods, 49(3):141–144.

Bertaina-Anglade, V., Enjuanes, E., Morillon, D., la Rochelle, C. D. 2006. The object recognition task in rats and mice: A simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. Journal of Pharmacological and Toxicological Methods, 54(2):99–105.

Bobade, V., Bodhankar, S. L., Aswar, U., Vishwaraman, M., Thakurdesai, P. 2015. Prophylactic effects of asiaticoside-based standardized extract of Centella asiatica (L.) Urban leaves on experimental migraine: Involvement of 5HT1A/1B receptors. Chinese Journal of Natural Medicines, 13(4):274– 282.

Coggins, C. R. E., Duchosal, F., Musy, C., Ventrone, R. 1981. Measurement of respiratory patterns in rodents using whole-body plethysmography and a pneumotachograph. Laboratory Animals, 15(2):137–140.

Creason, J. P. 1989. Data Evaluation and Statistical Analysis of Functional Observational Battery Data Using a Linear Models Approach. Journal of the American College of Toxicology, 8(1):157–169.

DeLorme, M. P., Moss, O. R. 2002. Pulmonary function assessment by whole-body plethysmography in restrained versus unrestrained mice. Journal of Pharmacological and Toxicological Methods, 47(1):1–10.

Dolhnikoff, M., Mauad, T., Ludwig, M. 1999. Extracellular Matrix and Oscillatory Mechanics of Rat Lung Parenchyma in Bleomycin-induced Fibrosis. American Journal of Respiratory and Critical Care Medicine, 160(5):1750–1757.

Goineau, S., Lemaire, M., Froget, G. 2013. Overview of Safety Pharmacology. Current Protocols in Pharmacology, 63(1):10.

Gras, J., Llenas, J., Palacios, J. M., Roberts, D. J. 1996. The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity. British Journal of Pharmacology, 119(2):187–188.

Hamdam, J., Sethu, S. 2013. Safety pharmacology — Current and emerging concepts. Toxicology and Applied Pharmacology, 273(2):229–241.

Hoymann, H. G. 2012. Lung Function Measurements in Rodents in Safety Pharmacology Studies. Frontiers in Pharmacology, 3:156.

Malik, M., Camm, A. J. 2001. Evaluation of Drug-Induced QT Interval Prolongation. Drug Safety, 24(5):323–351.

Mathiasen, J. R., Moser, V. C. 2018. The Irwin Test and Functional Observational Battery (FOB) for Assessing the Effects of Compounds on Behavior, Physiology, and Safety Pharmacology in Rodents. Current Protocols in Pharmacology, 83(1):e43.

McHugh, N. A., Miyamoto, M., Kelly, C. M., Karantabias, G. C., Gosselin, S. J. 2006. Evaluation of Respiratory Pharmacology in the Conscious Rat using Whole Body Bias Flow Plethysmography. Pharmacology (American Society for Pharmacology and Experimental Therapeutics), 20(4):674.

Moscardo, E., Fasdelli, N., Giarola, A., Tontodonati, M., Dorigatti, R. 2009. An optimised neurobehavioural observation battery integrated with the assessment of cardiovascular function in the beagle dog. Journal of Pharmacological and Toxicological Methods, 60(2):198–209.

Moss, A. J. 1999. The QT interval and torsade de pointes. Drug safety, 21(1):5–10.

Näslund, J., Haroutunian, V., Mohs, R., Davis, K. L., Davies, P., Greengard, P., Buxbaum, J. D. 2000. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. Jama, 283(12):1571–1578.

Natsume, Y., Patel, N. K., Tripathi, S. M., Nose, M., Bhutani, K. K. 2015. Kalyanaka ghrita: an example of intertextuality among the Bower manuscript, Charak samhita, Susruta samhita, Astangahrdayam samhita and Ayurvedic Formulary of India (AFI). Indian Journal of Traditional Knowledge, 14(4):519–524.

Rajput, S. K., Singh, J. N., Sharma, S. S. 2010. Evaluation of terfenadine and ketoconazole-induced QT prolongation in conscious telemetered guinea pigs. Pharmacological Reports, 62(4):683–688.

Ramos, A., Berton, O., Mormède, P., Chaouloff, F. 1997. A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behavioural Brain Research, 85(1):57–69.

Redfern, W., Carlsson, L., Davis, A., Lynch, W., Mackenzie, I., Palethorpe, S., Siegl, P., Strang, I., Sullivan, A., Wallis, R. 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research, 58(1):32–45.

Redfern, W. S., Strang, I., Storey, S., Heys, C., Barnard, C., Lawton, K., Hammond, T. G., Valentin, J.-P. 2005. Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds. Journal of Pharmacological and Toxicological Methods, 52(1):77–82.

Reinmann, B., Stocks, J., Frey, U. 2001. Assessment of an infant whole-body plethysmograph using an infant lung function model. European Respiratory Journal, 17(4):765–772.

Sinha, A. K. 1972. Colorimetric assay of catalase. Analytical biochemistry, 47(2):389–394.

Authors

Diddi Sneha Latha
Arulmozhi S
pharmarul@gmail.com (Primary Contact)
Diddi Sneha Latha, & Arulmozhi S. (2021). Safety Pharmacological studies of Kalyanaka ghrita. International Journal of Research in Pharmaceutical Sciences, 12(3), 2155–2163. Retrieved from https://ijrps.com/home/article/view/235

Article Details

No Related Submission Found